Recent Updates
Recently added Catalysts
Baker Bros. Advisors 13F Holdings (Q2 2026)
According to its SEC 13F filed on Aug 14, 2026, Baker Bros. Advisors reported 83 long positions worth $19.96B as of Jun 30, 2026. INCY is 17.5% of the portfolio and the top 10 holdings are 73%. Against Q1 2026 it opened 8 new positions, added to 16, trimmed 8 and exited 8. 22 holdings have a dated FDA decision or data readout in the next 90 days, and 38 more expect one in a stated window such as "H2 2026".
Holdings
Every position in the 13F, with the change since the fund's previous filing, how many of the 45 specialist funds also own it, and its next FDA catalyst. Option positions are labelled CALL or PUT.
| Stock | Company Name | Shares Held | Market Value | % of Portfolio | QoQ Change | Position Change | Also Held By | Stage | Next Catalyst |
|---|---|---|---|---|---|---|---|---|---|
 REPL | Replimune Group, Inc. | 11.05 M | 122.27 M | 0.6 | Unchanged | Commercial | None in 90 days | ||
 ABCL | AbCellera Biologics Inc. | 33.01 M | 259.15 M | 1.3 | Added +9% | Clinical | Oct 22, 2026 Phase 1/2 data presentation | ||
 CRNX | Crinetics Pharmaceuticals, Inc. | 2.35 M | 87.99 M | 0.4 | Unchanged | Commercial | None in 90 days | ||
 XNCR | Xencor, Inc. | 1.10 M | 17.74 M | 0.1 | Unchanged | Clinical | Oct 23, 2026 Phase 1 data readout | ||
 ABSI | Absci Corporation | 2.13 M | 24.74 M | 0.1 | Unchanged | Clinical | Expected second half of 2026 Phase 1/2a interim results | ||
 NRIX | Nurix Therapeutics, Inc. | 4.66 M | 113.02 M | 0.6 | Unchanged | Clinical | None in 90 days |
Top 20 Holdings
Size = share of the portfolio. Option positions show CALL or PUT.
Who else owns these stocks?
All Stock Holdings ranks every biotech stock by how many of the 45 specialist funds own it, and whether that number rose or fell this quarter. Click "of 45 funds" on any row above, or open the full view.
Questions about Baker Bros. Advisors's 13F
What does Baker Bros. Advisors own?
83 stocks worth $19.96B at Jun 30, 2026, as reported in its 13F, led by INCY (17.5% of the portfolio). The full list is in the Holdings table above.
What did it buy and sell last quarter?
Against Q1 2026: 8 new positions, 16 increases, 8 reductions and 8 full exits, from its 13F filings.
How current is this data?
13F filings are due 45 days after each quarter ends, so they show positions at quarter end, not today. The next filing (Q3 2026) is due Nov 16, 2026.
Why are some positions labelled CALL or PUT?
Those are option positions (calls and puts). The 13F reports them as the shares underlying the option, with no strike or expiry, so they are listed apart from share positions.
Source: SEC EDGAR Form 13F-HR filed by BAKER BROS. ADVISORS, accession 0001104659-26-097191, filed Aug 14, 2026. Values as filed; option positions are shown at the value of the underlying shares and labelled CALL or PUT.